
    
      This is a randomized, double-blind, placebo controlled study designed to evaluate the
      efficacy, safety, and PK of MEDI0382 administered as multiple daily SC doses to participants
      with T2DM. Approximately one hundred and seven participants will be enrolled across 6
      cohorts. In cohorts 1-3 the participants will be randomized to MEDI0382 or placebo (2:1). In
      Cohort 4, participants will be randomized to MEDI0382 or placebo (1:1). In cohort 5 and 6
      participants will be randomized to MEDI0382 or placebo (3:1).
    
  